Erez Vigodman
Erez Vigodman is an Israeli businessman, the former president and CEO of Teva Pharmaceutical Industries, the largest generic drug manufacturer in the world.Career
Vigodman served as the CEO of Makhteshim Agan until joining Teva, and was president and CEO of Strauss Group prior to this.
In January 2014, Vigodman, replaced Eyal Desheh as the CEO of Teva, with Desheh returning to his role as CFO.
In February 2017, Teva announced that Vigodman was stepping down as CEO with immediate effect and would be replace on an interim basis by the chairman, Yitzhak Peterburg, and Sol Barer would be the new chairman. This was a consequence of the $40 billion acquisition of Activis' generics division, which sent Teva spiralling down and saw its market capitalisation cut in half in less than a year. He is succeeded by Kåre Schultz, a Danish pharmaceutical veteran.
